Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

American Journal of Cardiology

Volumn 93, Issue 12, 2004, Pages 1558-1560

  Amit, Guy ^b   Rosen, Amit ^b   Wagshal, Avraham B ^b   Bonneh, Dan Y ^b   Liss, Tzvika ^b   Grosbard, Aviva ^b   Ilia, Reuven ^b   Katz, Amos ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; PROPAFENONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT; PRIORITY JOURNAL; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; DRUGS, GENERIC; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; PATIENT ADMISSION; PROPAFENONE; RECURRENCE; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 2942580749     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.02.071     Document Type: Article

References (11)

1. US Food and Drug Administration, Center for Drug Evaluation and Research. Approved drug products with therapeutic equivalence evaluations (Electronic Orange book), 23rd ed. 2003. Available at: http://www.fda.gov/cder/ob/default. htm. Accessed on February 5, 2004
2. Reiffel J.A. Formulation substitution and other pharmacokinetic variability underappreciated variables affecting antiarrrhythmic efficacy and safety in clinical practice. Am J Cardiol. 85:(suppl):2000;46D-52D
3. Siegel-Itzkovich J. Israel introduces generic drugs scheme. BMJ. 319:1999;592
4. Pouwels M.-J.M., Hoooymans P.M., van der Aa G.C., Gribnau F.W. Comparison of steady-state serum concentration of digoxin in tablets (Lanoxin) and capsules (Lanoxicap) in the elderly. Ann Pharmacother. 25:1991;1043-1046
5. Lam Y.W., Ereshefsky L., Toney G.B., Gonzales C. Branded versus generic clozapine bioavailability comparison and interchangeability issues. J Clin Psychiatry. 62:(suppl 5):2001;18-22
6. Sauro S.C., DeCarolis D.D., Pierpont G.L., Gornick C.C. Comparison of plasma concentrations for two amiodarone products. Ann Pharmacother. 36:2002;1682-1685
7. Reiffel J.A., Kowey P.R. Generic anthiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol. 85:2000;1151-1153
8. Pollak P.T. Altered metabolite concentration with amiodarone generic substitution cannot be observed without monitoring. Can J Cardiol. 17:2001;1159-1163
9. Milligan P.E., Banet G.A., Waterman A.D., Gatchel S.K., Gage B.F. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother. 36:2002;764-768
10. Haroldson J.A., Somerville K.T., Carlson S., Hanson J., Emery R.W., Lake K.D. A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients. J Heart Lung Transplant. 20:2000;372-374
11. Catelluci L. Congress considers funding head-to-head drug trials. Available at: www.theheart.org. Accessed August 25, 2003